Navigation Links
Watson's Generic Yaz(R) Receives FDA Approval
Date:11/29/2011

PARSIPPANY, N.J., Nov. 29, 2011 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) today announced that its subsidiary, Watson Laboratories, Inc., has received approval from the United States Food and Drug Administration for its Abbreviated New Drug Application for Vestura(TM) (3 mg drospirenone and 0.02 mg ethinyl estradiol), a generic version of Bayer's Yaz(R) oral contraceptive product.  Watson is currently involved in patent litigation with Bayer concerning this product. 

Yaz(R) had total U.S. sales of $173 million for the twelve months ending September 30, 2011, according to IMS Health. Watson's Vestura(TM) is indicated for the prevention of pregnancy and for the treatment of moderate acne in women at least 14 years old only if the patient desires an oral contraceptive for birth control.

About Watson Pharmaceuticals, Inc.
Watson Pharmaceuticals, Inc. is an integrated global specialty pharmaceutical company. The Company is engaged in the development, manufacturing, marketing and distribution of generic pharmaceuticals and specialized branded pharmaceutical products focused on Urology and Women's Health. Watson has operations in many of the world's established and growing international markets.

For press release and other company information, visit Watson Pharmaceuticals' Web site at http://www.watson.com.

Forward-Looking Statement
Statements contained in this press release that refer to non-historical facts are forward-looking statements that reflect Watson's current perspective of existing information as of the date of this release. It is important to note that Watson's goals and expectations are not predictions of actual performance. Actual results may differ materially from Watson's current expectations depending upon a number of factors, risks and uncertainties affecting Watson's business. These factors include, among others, the difficulty of predicting the timing and outcome of the pending patent litigation; the impact of competitive products and pricing; the timing and success of product launches; difficulties or delays in manufacturing; the availability and pricing of third party sourced products and materials; successful compliance with FDA and other governmental regulations applicable to Watson and its third party manufacturers' facilities, products and/or businesses; changes in the laws and regulations, including Medicare and Medicaid, affecting among other things, pricing and reimbursement of pharmaceutical products; and such other risks and uncertainties detailed in Watson's periodic public filings with the Securities and Exchange Commission, including but not limited to Watson's quarterly report on form 10-Q for the quarter ended September 30, 2011 and Watson's annual report on Form 10-K for the year ended December 31, 2010. Except as expressly required by law, Watson disclaims any intent or obligation to update these forward-looking statements.

YAZ(R) is a registered trademark of Bayer Schering Pharma Aktiengesellschaft.

(Logo: http://photos.prnewswire.com/prnh/20100121/LA41294LOGO ) CONTACTS:Investors: 

Patty Eisenhaur 

(862) 261-8141 Media: 

Charlie Mayr 

(862) 261-8030


'/>"/>
SOURCE Watson Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. K-V Pharmaceutical Announces Divestiture of Generics Business to Zydus
2. Mylan Launches Generic Version of Percodan® Tablets
3. Mylan Launches Generic Version of Sandostatin®
4. Due to Generic Erosion, the Hypertension Drug Market Will Decline by $3 Billion from 2009 to 2019
5. Generic Drug Sector Gets Better Information on API Manufacturing Costs from Thomson Reuters and Rondaxe Enterprises
6. Thomson Reuters Explores the Opportunities and Challenges of Entering the Japanese Generic Drug Market
7. Hypertension Drug Market Will Experience Only Modest Annual Decline Through 2018, Despite Generic Erosion Of Many Branded Agents
8. Forty-two of Simceres Generic Drugs Enter Chinas Essential Drug List
9. GPhA Says BIO Cries Wolf on Senate Biogenerics Proposal
10. Caraco Pharmaceutical Laboratories, Ltd. Markets Generic Casodex(R) Tablets
11. Mylan Receives FDA Approval for Generic Version of Prostate Cancer Treatment Casodex(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... ... December 07, 2016 , ... Huffman Engineering, Inc. , ... Wonderware Certified System Integrator Partner. Huffman Engineering is the only Nebraska-based company ... System Integrator Partner certification gives customers confidence that our engineers are fully trained ...
(Date:12/7/2016)... EDMONTON , Dec. 7, 2016 /PRNewswire/ - ... the development and commercialization of immunotherapeutic products for ... has entered into an Antibody Manufacturing Development Program ... , USA) for its oregovomab antibody product. ... its Phase IIb clinical study in ovarian cancer ...
(Date:12/7/2016)... Ontario , Dec. 7, 2016  Nordion, ... with General Atomics (GA), welcome today,s award by ... Nuclear Security Administration (NNSA) of the Phase II ... project with Nordion and the University of Missouri ... II funding will support the establishment of a ...
(Date:12/7/2016)... The report "Acrylic Processing Aid Market by Polymer Type (PVC), Fabrication Process (Extrusion, Injection Molding), ... 2026", published by MarketsandMarkets, the global market size was USD 645.4 Million in ... of CAGR of 6.2% between 2016 and 2026. ... ... , , ...
Breaking Biology Technology:
(Date:12/5/2016)... 2016  The Office of Justice Programs, National ... Scans Enhance or Replace Medico Legal Autopsies?" on ... or replacing forensic autopsies with postmortem X-ray computed ... In response to recommendations made by The National ... scans as a potential component of medicolegal death ...
(Date:11/29/2016)... , Nov. 29, 2016 BioDirection, a privately ... products for the objective detection of concussion and other ... has successfully completed a meeting with the U.S. Food ... blood test Pre-Submission Package. During the meeting company representatives ... as a precursor to commencement of a planned pilot ...
(Date:11/22/2016)... According to the new market research report "Biometric ... Signature, Voice), Multi-Factor), Component (Hardware and Software), Function (Contact and Non-contact), Application, ... is expected to grow from USD 10.74 Billion in 2015 to reach ... and 2022. Continue Reading ... ...
Breaking Biology News(10 mins):